Varénicline (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Varénicline" in French language version.

refsWebsite

Global rank French rank

7nih.gov

4^th place

12^th place

5doi.org

2^nd place

3^rd place

5bmj.com

1,226^th place

347^th place

3issn.org

57^th place

4^th place

3jamanetwork.com

2,650^th place

689^th place

2web.archive.org

1^st place

2fda.gov

447^th place

1,409^th place

2ama-assn.org

3,257^th place

1,028^th place

1qmul.ac.uk

1,735^th place

168^th place

1vidal.fr

low place

910^th place

1vitaemed.com

low place

1sante.fr

8,603^rd place

517^th place

1wikiwix.com

194^th place

17^th place

1archive.is

87^th place

20^th place

1googleusercontent.com

243^rd place

21^st place

1biomedcentral.com

2,747^th place

1,253^rd place

1cancer.org

3,680^th place

5,075^th place

1chantix.com

low place

1nytimes.com

7^th place

28^th place

1informahealthcare.com

low place

5,838^th place

1hc-sc.gc.ca

low place

3,517^th place

ama-assn.org

archinte.ama-assn.org

Smoking Cessation With Varenicline, a Selective 42 Nicotinic Receptor Partial Agonist. Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up Arch Intern Med -- Smoking Cessation With Varenicline, a Selective {alpha}4beta2 Nicotinic Receptor Partial Agoni st: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up, Aug 14/28, 2006, Nides et al. 166 (15): 1561 Arch Intern Med. 2006;166:1561-1568.
Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji A, Use of Varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates, Arch Intern Med, 2011;171:770-777

archive.is

« ansm.sante.fr/S-informer/Press… »^{(Archive.org • Wikiwix • Archive.is • Google • Que faire ?)}.

biomedcentral.com

LK Leung, « Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis », BMC clinical pharmacology, vol. 11, n^o 1,‎ septembre 2011, p. 15 (PMID 21955317, PMCID 3192741, DOI 10.1186/1472-6904-11-15, lire en ligne)

bmj.com

Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D, Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study, BMJ 2013;347:f5704
Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D, Risk of neuropsychiatric events associated with varenicline: systematic review and meta-analysis; BMJ, 2015;350: h1109
Fagerström K, Gilljam H, Metcalfe M, Tonstad S, Messig M, Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial, BMJ, 2010;341:c6549

thorax.bmj.com

(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, n^o 10,‎ 1^er octobre 2017, p. 905–911 (ISSN 0040-6376 et 1468-3296, PMID 28473506, DOI 10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le 11 octobre 2017)
H-J Aubin & al., « Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial », Thorax, BMJ Publishing Group Ltd & British Thoracic Society, vol. 63,‎ 8 février 2008, p. 717-724 (DOI 10.1136/thx.2007.090647, lire en ligne)

cancer.org

(en) American Cancer Society, « Cancer Drug Guide: Varenicline » (consulté le 19 janvier 2008)

chantix.com

(en) « Important Information about Chantix » (consulté en mai 2008)

doi.org

dx.doi.org

LK Leung, « Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis », BMC clinical pharmacology, vol. 11, n^o 1,‎ septembre 2011, p. 15 (PMID 21955317, PMCID 3192741, DOI 10.1186/1472-6904-11-15, lire en ligne)
(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, n^o 10,‎ 1^er octobre 2017, p. 905–911 (ISSN 0040-6376 et 1468-3296, PMID 28473506, DOI 10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le 11 octobre 2017)
H-J Aubin & al., « Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial », Thorax, BMJ Publishing Group Ltd & British Thoracic Society, vol. 63,‎ 8 février 2008, p. 717-724 (DOI 10.1136/thx.2007.090647, lire en ligne)
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20,‎ 2022, p. 46 (ISSN 1617-9625, PMID 35611069, PMCID 9086158, DOI 10.18332/tid/146567, lire en ligne, consulté le 24 décembre 2022)
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205,‎ 1^er décembre 2019, p. 107631 (ISSN 1879-0046, PMID 31678838, DOI 10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le 27 décembre 2022)

fda.gov

(en) « Early Communication About an Ongoing Safety Review: Varenicline (marketed as Chantix) » [archive du 5 décembre 2007], United States Food and Drug Administration, november 20 2007 (consulté le 21 novembre 2007)
(en) FDA, « Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban » (consulté le 1^er juillet 2009)

googleusercontent.com

webcache.googleusercontent.com

« ansm.sante.fr/S-informer/Press… »^{(Archive.org • Wikiwix • Archive.is • Google • Que faire ?)}.

hc-sc.gc.ca

Santé Canada. Summary Basis of Decision - Champix. 30 janvier 2008. Summary Basis of Decision (SBD): Champix

informahealthcare.com

Hedlund AJ, Broderick M, Shah N, Cantrell L. Varenicline overdose in a teenager, Clin Toxicol (Phila), 2009;47:371

issn.org

portal.issn.org

(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, n^o 10,‎ 1^er octobre 2017, p. 905–911 (ISSN 0040-6376 et 1468-3296, PMID 28473506, DOI 10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le 11 octobre 2017)
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20,‎ 2022, p. 46 (ISSN 1617-9625, PMID 35611069, PMCID 9086158, DOI 10.18332/tid/146567, lire en ligne, consulté le 24 décembre 2022)
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205,‎ 1^er décembre 2019, p. 107631 (ISSN 1879-0046, PMID 31678838, DOI 10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le 27 décembre 2022)

jamanetwork.com

archinte.jamanetwork.com

Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR, Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates, Arch Intern Med, 2011;171:770-777
Hajek P, McRobbie H, Smith KM, Phillips A, Cornwall D, Dhanji A, Increasing Varenicline dose in smokers who do not respond to the standard dosage, JAMA Intern Med, 2015;175:266-271

jamanetwork.com

Baker TB, Piper ME, Smith SS, Bolt DM, Stein JH, Fiore MC. Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation: a randomized clinical trial, JAMA, 2021:326:1485-1493

nih.gov

ncbi.nlm.nih.gov

LK Leung, « Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis », BMC clinical pharmacology, vol. 11, n^o 1,‎ septembre 2011, p. 15 (PMID 21955317, PMCID 3192741, DOI 10.1186/1472-6904-11-15, lire en ligne)
(en) Daniel Kotz, Wolfgang Viechtbauer, Colin R. Simpson et Onno C. P. van Schayck, « Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease », Thorax, vol. 72, n^o 10,‎ 1^er octobre 2017, p. 905–911 (ISSN 0040-6376 et 1468-3296, PMID 28473506, DOI 10.1136/thoraxjnl-2017-210067, lire en ligne, consulté le 11 octobre 2017)
(en) Jorenby D E & al., « Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial », JAMA, vol. 296, n^o 1,‎ 5 juillet 2006, p. 56–63 (PMID 16820547)
Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20,‎ 2022, p. 46 (ISSN 1617-9625, PMID 35611069, PMCID 9086158, DOI 10.18332/tid/146567, lire en ligne, consulté le 24 décembre 2022)
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205,‎ 1^er décembre 2019, p. 107631 (ISSN 1879-0046, PMID 31678838, DOI 10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le 27 décembre 2022)

pubmed.ncbi.nlm.nih.gov

Philip Tønnesen, David Lawrence et Serena Tonstad, « Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial », Tobacco Induced Diseases, vol. 20,‎ 2022, p. 46 (ISSN 1617-9625, PMID 35611069, PMCID 9086158, DOI 10.18332/tid/146567, lire en ligne, consulté le 24 décembre 2022)
Awirut Oon-Arom, Surinporn Likhitsathain et Manit Srisurapanont, « Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials », Drug and Alcohol Dependence, vol. 205,‎ 1^er décembre 2019, p. 107631 (ISSN 1879-0046, PMID 31678838, DOI 10.1016/j.drugalcdep.2019.107631, lire en ligne, consulté le 27 décembre 2022)